These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22493422)

  • 1. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
    Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
    J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    Atkins MB; Hidalgo M; Stadler WM; Logan TF; Dutcher JP; Hudes GR; Park Y; Liou SH; Marshall B; Boni JP; Dukart G; Sherman ML
    J Clin Oncol; 2004 Mar; 22(5):909-18. PubMed ID: 14990647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
    J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.
    Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF
    Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
    J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
    J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
    Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
    Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
    Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
    Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
    Mehta A; Sonpavde G; Escudier B
    Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
    Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
    Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
    Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
    J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
    Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
    Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.
    De Luca A; Normanno N
    IDrugs; 2010 Sep; 13(9):636-45. PubMed ID: 20799147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
    Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
    Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.